Redefining Hormone Sensitive Disease in Advanced Prostate Cancer

por Hou, Xiaoyu, Flaig, Thomas W.
Publicado 2012

Geriatric considerations in the treatment of advanced prostate cancer

por Kessler, Elizabeth R., Flaig, Thomas W.
Publicado 2014

Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

por Boxley, Peter, Plets, Melissa, Flaig, Thomas W.
Publicado 2020

miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2

por Yang, Xiaoping, Bemis, Lynne, Su, Lih-Jen, Gao, Dexiang, Flaig, Thomas W.
Publicado 2012

Renal cell carcinoma: a review of biology and pathophysiology

por Nabi, Shahzaib, Kessler, Elizabeth R., Bernard, Brandon, Flaig, Thomas W., Lam, Elaine T.
Publicado 2018

Burden of Cardiovascular Disease in Immune Checkpoint Inhibitor–Treated Patients: Reconciling Adjudicated and Coded Outcomes

por Kondapalli, Lavanya, Hsia, Judith, Miller, Ronni, Flaig, Thomas W., Bonaca, Marc P.
Publicado 2022

Treatment evolution for metastatic castration‐resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real‐world data

por Flaig, Thomas W., Potluri, Ravi C., Ng, Yvette, Todd, Mary B., Mehra, Maneesha
Publicado 2015

Clinical significance of sunitinib‐associated macrocytosis in metastatic renal cell carcinoma

por Bourlon, Maria T., Gao, Dexiang, Trigero, Sara, Clemons, Julia E., Breaker, Kathryn, Lam, Elaine T., Flaig, Thomas W.
Publicado 2016

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer

por Nordeen, Steven K., Su, Lih-Jen, Osborne, Gregory A., Hayman, Perry M., Orlicky, David J., Wessells, Veronica M., van Bokhoven, Adrie, Flaig, Thomas W.
Publicado 2021

Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT)

por Altoos, Basel, Amini, Arya, Yacoub, Muthanna, Bourlon, Maria T., Kessler, Elizabeth E., Flaig, Thomas W., Fisher, Christine M., Kavanagh, Brian D., Lam, Elaine T., Karam, Sana D.
Publicado 2015

The Antineoplastic Activity of Photothermal Ablative Therapy with Targeted Gold Nanorods in an Orthotopic Urinary Bladder Cancer Model

por Yang, Xiaoping, Su, Lih-Jen, La Rosa, Francisco G., Smith, Elizabeth Erin, Schlaepfer, Isabel R., Cho, Suehyun K., Kavanagh, Brian, Park, Wounjhang, Flaig, Thomas W.
Publicado 2017

Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium

por Flaig, Thomas W., Kamat, Ashish M., Hansel, Donna, Ingersoll, Molly A., Barton Grossman, H., Mendelsohn, Cathy, DeGraff, David, Liao, Joseph C., Taylor, John A.
Publicado 2017

Simultaneous Activation of Kras and Inactivation of p53 Induces Soft Tissue Sarcoma and Bladder Urothelial Hyperplasia

por Yang, Xiaoping, La Rosa, Francisco G., Genova, Elizabeth Erin, Huber, Kendra, Schaack, Jerome, DeGregori, James, Serkova, Natalie J., Li, Yuan, Su, Lih-Jen, Kessler, Elizabeth, Flaig, Thomas W.
Publicado 2013

A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma

por Kessler, Elizabeth R., Callihan, Eryn, Hu, Junxiao, Eule, Corbin, Srivastava, Geetika, Kemme, Douglas J., Iruku, Praveena, Rana, Vishal, Moore, James, Schuster, Steven R., Amirault, Mali, Flaig, Thomas W., Lam, Elaine T.
Publicado 2023

Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer

por Kessler, Elizabeth R., Su, Lih-Jen, Gao, Dexiang, Torkko, Kathleen C., Wacker, Michael, Anduha, Mary, Chronister, Nicole, Maroni, Paul, Crawford, E. David, Flaig, Thomas W., Glode, L. Michael, Lam, Elaine T.
Publicado 2018

Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade

por Flaig, Thomas W., Salzmann-Sullivan, Maren, Su, Lih-Jen, Zhang, Zhiyong, Joshi, Molishree, Gijón, Miguel A., Kim, Jihye, Arcaroli, John J., Van Bokhoven, Adrie, Lucia, M. Scott, La Rosa, Francisco G., Schlaepfer, Isabel R.
Publicado 2017

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

por Lam, Elaine T., Wong, Michael K. K., Agarwal, Neeraj, Redman, Bruce G., Logan, Theodore, Gao, Dexiang, Flaig, Thomas W., Lewis, Karl, Poust, Jamie, Monk, Paul, Jarkowski, Anthony, Sendilnathan, Arun, Bolden, Marcus, Kuzel, Timothy M., Olencki, Thomas
Publicado 2014

Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

por de Bono, Johann S., Smith, Matthew R., Saad, Fred, Rathkopf, Dana E., Mulders, Peter F.A., Small, Eric J., Shore, Neal D., Fizazi, Karim, De Porre, Peter, Kheoh, Thian, Li, Jinhui, Todd, Mary B., Ryan, Charles J., Flaig, Thomas W.
Publicado 2016

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

por Bhatia, Shailender, Curti, Brendan, Ernstoff, Marc S, Gordon, Michael, Heath, Elisabeth I, Miller, Wilson H, Puzanov, Igor, Quinn, David I, Flaig, Thomas W, VanVeldhuizen, Peter, Byrnes-Blake, Kelly, Freeman, Jeremy A, Bittner, Rachel, Hunder, Naomi, Souza, Sonia, Thompson, John A
Publicado 2014

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

por Rosenberg, Jonathan, Sridhar, Srikala S., Zhang, Jingsong, Smith, David, Ruether, Dean, Flaig, Thomas W., Baranda, Joaquina, Lang, Joshua, Plimack, Elizabeth R., Sangha, Randeep, Heath, Elisabeth I., Merchan, Jamie, Quinn, David I., Srinivas, Sandy, Milowsky, Matthew, Wu, Chunzhang, Gartner, Elaina M., Zuo, Peiying, Melhem-Bertrandt, Amal, Petrylak, Daniel P.
Publicado 2020